Total Payments
$461,951
2024 Payments
$59,108
Companies
16
Transactions
522
Medicare Patients
591
Medicare Billing
$57,173
Payment Breakdown by Category
Other$309,453 (67.0%)
Consulting$77,229 (16.7%)
Travel$59,154 (12.8%)
Food & Beverage$12,352 (2.7%)
Research$3,749 (0.8%)
Education$14.50 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $302,378 | 116 | 65.5% |
| Consulting Fee | $77,229 | 27 | 16.7% |
| Travel and Lodging | $59,154 | 215 | 12.8% |
| Food and Beverage | $12,352 | 145 | 2.7% |
| Honoraria | $7,075 | 3 | 1.5% |
| Unspecified | $3,749 | 15 | 0.8% |
| Education | $14.50 | 1 | 0.0% |
Payments by Type
General
$458,203
507 transactions
Research
$3,749
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $333,880 | 317 | $0 (2024) |
| Lilly USA, LLC | $44,817 | 51 | $0 (2024) |
| Medical Device Business Services, Inc. | $43,351 | 57 | $0 (2023) |
| Johnson & Johnson Medical Devices & Diagnostics Group - Latin America, L.L.C. | $7,435 | 10 | $0 (2018) |
| Ethicon US, LLC | $7,400 | 19 | $0 (2019) |
| Novo Nordisk AS | $4,813 | 10 | $0 (2023) |
| Orexigen Therapeutics, Inc. | $4,160 | 4 | $0 (2017) |
| Regeneron Pharmaceuticals, Inc. | $3,921 | 13 | $0 (2024) |
| Covidien LP | $3,850 | 2 | $0 (2020) |
| Eli Lilly and Company | $3,097 | 25 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $59,108 | 78 | Lilly USA, LLC ($44,817) |
| 2023 | $19,947 | 20 | Novo Nordisk Inc ($17,691) |
| 2022 | $80,068 | 72 | Novo Nordisk Inc ($79,632) |
| 2021 | $42,231 | 40 | Novo Nordisk Inc ($42,231) |
| 2020 | $47,687 | 34 | Novo Nordisk Inc ($42,451) |
| 2019 | $80,436 | 109 | Novo Nordisk Inc ($70,095) |
| 2018 | $77,097 | 94 | Medical Device Business Services, Inc. ($34,592) |
| 2017 | $55,378 | 75 | Novo Nordisk Inc ($42,576) |
All Payment Transactions
522 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,250.00 | General |
| 12/13/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 12/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $209.58 | General |
| 12/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $39.68 | General |
| 12/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $39.68 | General |
| 12/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $31.75 | General |
| 12/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $31.75 | General |
| 12/02/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: Obesity | ||||||
| 11/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $773.33 | General |
| 11/19/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Travel and Lodging | Cash or cash equivalent | $168.84 | General |
| Category: Obesity | ||||||
| 11/19/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | Cash or cash equivalent | $40.28 | General |
| Category: Obesity | ||||||
| 11/19/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Travel and Lodging | Cash or cash equivalent | $10.20 | General |
| Category: Obesity | ||||||
| 11/18/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: Obesity | ||||||
| 11/18/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,325.00 | General |
| Category: Obesity | ||||||
| 11/13/2024 | Currax Pharmaceuticals LLC | CONTRAVE (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Obesity | ||||||
| 10/31/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: Obesity | ||||||
| 10/18/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: Obesity | ||||||
| 10/04/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,050.00 | General |
| Category: Obesity | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $339.88 | Research |
| Study: A MASTER PROTOCOL OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDIES OF SIRNA GENE SILENCING FOR THE TREATMENT OF NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN PARTICIPANTS WITH GENETIC RISK FACTORS | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $298.20 | Research |
| Study: A MASTER PROTOCOL OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDIES OF SIRNA GENE SILENCING FOR THE TREATMENT OF NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN PARTICIPANTS WITH GENETIC RISK FACTORS | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $121.99 | Research |
| Study: A MASTER PROTOCOL OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDIES OF SIRNA GENE SILENCING FOR THE TREATMENT OF NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN PARTICIPANTS WITH GENETIC RISK FACTORS | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $97.00 | Research |
| Study: A MASTER PROTOCOL OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDIES OF SIRNA GENE SILENCING FOR THE TREATMENT OF NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN PARTICIPANTS WITH GENETIC RISK FACTORS | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $48.99 | Research |
| Study: A MASTER PROTOCOL OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDIES OF SIRNA GENE SILENCING FOR THE TREATMENT OF NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN PARTICIPANTS WITH GENETIC RISK FACTORS | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $48.99 | Research |
| Study: A MASTER PROTOCOL OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDIES OF SIRNA GENE SILENCING FOR THE TREATMENT OF NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN PARTICIPANTS WITH GENETIC RISK FACTORS | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $33.99 | Research |
| Study: A MASTER PROTOCOL OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDIES OF SIRNA GENE SILENCING FOR THE TREATMENT OF NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN PARTICIPANTS WITH GENETIC RISK FACTORS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MASTER PROTOCOL OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDIES OF SIRNA GENE SILENCING FOR THE TREATMENT OF NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN PARTICIPANTS WITH GENETIC RISK FACTORS | Regeneron Pharmaceuticals, Inc. | $1,704 | 9 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | Eli Lilly and Company | $1,287 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF REGN4461, A LEPTIN RECEPTOR AGONIST ANTIBODY, IN PATIENTS WITH GENERALIZED LIPODYSTROPHY | Regeneron Pharmaceuticals, Inc. | $466.62 | 2 |
| A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | Eli Lilly and Company | $291.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 81 | 133 | $27,689 | $7,429 |
| 2022 | 7 | 186 | 359 | $63,760 | $16,620 |
| 2021 | 6 | 131 | 234 | $47,751 | $12,385 |
| 2020 | 6 | 193 | 364 | $87,495 | $20,739 |
Total Patients
591
Total Services
1,090
Medicare Billing
$57,173
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 24 | 52 | $8,972 | $3,158 | 35.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 17 | 24 | $7,275 | $1,404 | 19.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 18 | $5,430 | $1,290 | 23.8% |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | Office | 2023 | 16 | 25 | $3,600 | $1,043 | 29.0% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 12 | 14 | $2,412 | $534.10 | 22.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 67 | 192 | $37,347 | $10,527 | 28.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 11 | 16 | $4,650 | $1,403 | 30.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 14 | 16 | $4,678 | $1,149 | 24.6% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 11 | 12 | $3,572 | $932.06 | 26.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 12 | 16 | $3,070 | $785.83 | 25.6% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 28 | 45 | $5,838 | $783.84 | 13.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 12 | 14 | $2,680 | $775.50 | 28.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 16 | 22 | $1,490 | $231.47 | 15.5% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2022 | 15 | 26 | $435.20 | $31.46 | 7.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 43 | 101 | $23,038 | $5,588 | 24.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 24 | 40 | $7,075 | $2,031 | 28.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 17 | 26 | $4,615 | $1,659 | 35.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 13 | 15 | $7,043 | $1,489 | 21.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 12 | 12 | $4,449 | $1,387 | 31.2% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 11 | 19 | $1,244 | $198.36 | 15.9% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2021 | 11 | 21 | $287.11 | $32.72 | 11.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 74 | 219 | $51,707 | $12,309 | 23.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 32 | 33 | $16,156 | $3,468 | 21.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 34 | 56 | $8,481 | $2,034 | 24.0% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2020 | 15 | 15 | $5,438 | $1,212 | 22.3% |
About Dr. Christopher Still, D.O
Dr. Christopher Still, D.O is a Internal Medicine healthcare provider based in Danville, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1710935739.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Still, D.O has received a total of $461,951 in payments from pharmaceutical and medical device companies, with $59,108 received in 2024. These payments were reported across 522 transactions from 16 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($302,378).
As a Medicare-enrolled provider, Still has provided services to 591 Medicare beneficiaries, totaling 1,090 services with total Medicare billing of $57,173. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Danville, PA
- Active Since 05/04/2006
- Last Updated 08/10/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1710935739
Products in Payments
- Saxenda (Drug) $258,814
- Wegovy (Drug) $51,715
- ZEPBOUND (Drug) $38,217
- ECHELON FLEX Stapler (Device) $23,962
- ECHELON ENDOPATH Stapler (Device) $21,655
- HARMONIC Product Family (Device) $10,174
- CONTRAVE (Drug) $7,160
- Sonicision (Device) $3,850
- CONTOUR (Device) $727.20
- Echelon Flex (Device) $89.86
- ENDOPATH XCEL Trocar Portfolio (Device) $27.87
- Kanuma (Drug) $14.50
- INJECTAFER (Drug) $12.61
- STELARA (Biological) $12.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Danville
Dr. Brendan Carry, M.d, M.D
Internal Medicine — Payments: $209,824
Internal Medicine $209,824
Prince Anand, M.d, M.D
Internal Medicine — Payments: $188,555
Internal Medicine $188,555
Jessica Mckee, D.o, D.O
Internal Medicine — Payments: $57,390
Internal Medicine $57,390
Michael Caplan, Md, MD
Internal Medicine — Payments: $41,374
Internal Medicine $41,374
Dr. Mark Reginato, M.d, M.D
Internal Medicine — Payments: $23,997
Internal Medicine $23,997
Mobasser Mahmood, M.d, M.D
Internal Medicine — Payments: $23,322
Internal Medicine $23,322